Hemochromatosis Statistics

Untreated people with the HFE C282Y mutation in both copies face a 20 to 30% risk of developing cirrhosis. In those with hemochromatosis related cirrhosis, hepatocellular carcinoma risk is about 200 times higher than in the general population. Other major complications also cluster in predictable ranges, including diabetes in 30 to 50% of symptomatic patients at diagnosis and cardiac arrhythmia accounting for 30% of mortality.

Key Takeaways

Cirrhosis develops in 20-30% of untreated C282Y homozygotes
Hepatocellular carcinoma risk 200-fold increased in HH cirrhosis vs general population
Diabetes mellitus in 30-50% of symptomatic HH patients at diagnosis
The C282Y mutation in HFE gene accounts for 80-90% of hereditary hemochromatosis cases in populations of Northern European origin
H63D mutation in HFE is a common polymorphism with allele frequency of 15-20% in Europeans but rarely pathogenic alone
Compound heterozygosity for C282Y/H63D occurs in 2-5% of Caucasians and increases iron absorption mildly
Hereditary hemochromatosis affects approximately 1 in 200 to 1 in 300 individuals of Northern European descent as homozygous for the C282Y mutation in the HFE gene
In the United States, the carrier frequency for HFE C282Y mutation is about 1 in 10 among Caucasians
Global prevalence of hereditary hemochromatosis type 1 (HFE-related) is estimated at 0.3-0.5% in populations of European ancestry
Transferrin saturation >45% is first diagnostic marker, present in 90% of C282Y homozygotes before age 50
Serum ferritin >1000 ng/mL indicates significant iron overload in hemochromatosis
Liver biopsy shows grade 4 siderosis (4+ iron in hepatocytes) in 80% of untreated HH patients
Phlebotomy response: ferritin decline 30-50 mg/L per 500 mL blood removed
Therapeutic phlebotomy targets ferritin <50 ng/mL, reducing mortality by 50%
Iron chelation with deferasirox 20-30 mg/kg/day normalizes ferritin in 70% of transfusion-dependent HH

Early phlebotomy prevents severe organ damage, cutting cirrhosis and cancer risk in hereditary hemochromatosis.

01 · Category

Complications And Prognosis23 stats

Cirrhosis develops in 20-30% of untreated C282Y homozygotes

Hepatocellular carcinoma risk 200-fold increased in HH cirrhosis vs general population

Diabetes mellitus in 30-50% of symptomatic HH patients at diagnosis

HCC annual incidence 2-4% in cirrhotic HH

Cardiac arrhythmia death accounts for 30% of mortality in untreated HH

Hypogonadotropic hypogonadism leads to infertility in 25% untreated men

Osteoporosis fracture risk 3-fold higher in HH men under 60

Dilated cardiomyopathy in 15% of advanced untreated cases, ejection fraction <40%

5-year survival post-HCC diagnosis in HH is 20%

Arthropathy progresses despite treatment in 20-30%, requiring joint replacement in 5%

Liver failure mortality reduced from 60% to 10% with early phlebotomy

Parkinson's disease risk increased 2-fold in HH due to brain iron

Impotence persists in 20% despite treatment if longstanding

Secondary hemochromatosis from transfusions increases cardiac death by 50%

Cholelithiasis in 20-30% due to cirrhosis

Porphyria cutanea tarda complicates 20% of HH cases, blisters heal slower

10-year life expectancy normalized with treatment if no cirrhosis

HCC multifocal in 40% of HH cirrhotics at diagnosis

Hearing loss bilateral severe in 10% advanced cases

Splenomegaly with hypersplenism in 15% cirrhotic HH

Esophageal varices bleed risk 20-30% per year untreated cirrhosis

Neurodegeneration mimics ALS in rare advanced iron brain deposition

Diabetes insulin dependence in 60% of HH cases, nephropathy risk +2x

Interpretation

Complications And Prognosis Interpretation

In untreated hemochromatosis, prognosis is shaped by major organ complications with cirrhosis developing in 20 to 30% of C282Y homozygotes and hepatocellular carcinoma occurring at a 200-fold higher risk, while cardiac arrhythmias account for 30% of deaths, diabetes appears in 30 to 50% of symptomatic cases, and fertility is impaired in 25% of untreated men due to hypogonadotropic hypogonadism.

02 · Category

Genetics And Molecular Biology25 stats

The C282Y mutation in HFE gene accounts for 80-90% of hereditary hemochromatosis cases in populations of Northern European origin

H63D mutation in HFE is a common polymorphism with allele frequency of 15-20% in Europeans but rarely pathogenic alone

Compound heterozygosity for C282Y/H63D occurs in 2-5% of Caucasians and increases iron absorption mildly

Type 2A hemochromatosis is caused by mutations in HJV (hemojuvelin) gene on chromosome 1q21

Ferroportin (SLC40A1) gene mutations cause type 4 hemochromatosis with autosomal dominant inheritance

HAMP gene (hepcidin) mutations lead to type 2B juvenile hemochromatosis, autosomal recessive

TFR2 gene mutations cause type 3 hemochromatosis, rare, autosomal recessive, chromosome 7q22

Neonatal hemochromatosis is associated with maternal-fetal alloimmunity to alpha-1-antitrypsin, not primarily genetic

Over 40 pathogenic mutations identified in HFE gene, but C282Y is the most penetrant

S65C mutation in HFE is rare (allele frequency <0.5%) and associated with mild iron overload

Hepcidin, encoded by HAMP, is the master regulator of iron homeostasis, deficient in most hemochromatosis types

Matriptase-2 (TMPRSS6) loss-of-function mutations cause iron-refractory iron deficiency anemia, opposite of hemochromatosis, but relevant pathway

BMP6 mutations are linked to rare iron overload disorders resembling hemochromatosis

The C282Y mutation substitutes tyrosine for cysteine at position 282, disrupting HFE-beta2-microglobulin interaction

HJV acts as BMP co-receptor, enhancing hepcidin transcription; mutations abolish this

Ferroportin p.Val162del mutation causes classical type 4B hemochromatosis with iron accumulation in Kupffer cells

Genetic penetrance varies; C282Y homozygotes have 2-4 fold increased transferrin saturation

Rare HFE mutations like I105T and G93R are associated with increased ferritin without C282Y

Polygenic inheritance influences penetrance, with TMPRSS6 variants modulating HFE effects

Autosomal recessive inheritance for HFE-related HH; both alleles must be mutated for disease

H63D/C282Y compound heterozygotes have 1.5-2x normal ferritin in 20-30% of cases

Next-generation sequencing identifies novel variants in non-HFE hemochromatosis in 10% of unexplained cases

Mouse models: Hfe knockout recapitulates iron overload phenotype

Hepcidin knockout mice die of iron overload by 9 months

Genetic testing for HFE detects 90% of HH cases in appropriate populations

Interpretation

Genetics And Molecular Biology Interpretation

In the genetics and molecular biology of hemochromatosis, the HFE C282Y mutation explains 80 to 90 percent of hereditary cases in Northern Europeans, while other HFE variants like H63D usually cause little risk alone and only account for a small 2 to 5 percent share of disease when combined as C282Y/H63D, with rarer forms tied to specific gene defects such as HJV for type 2A and SLC40A1 or HAMP for later types.

03 · Category

Prevalence And Epidemiology30 stats

Hereditary hemochromatosis affects approximately 1 in 200 to 1 in 300 individuals of Northern European descent as homozygous for the C282Y mutation in the HFE gene

In the United States, the carrier frequency for HFE C282Y mutation is about 1 in 10 among Caucasians

Global prevalence of hereditary hemochromatosis type 1 (HFE-related) is estimated at 0.3-0.5% in populations of European ancestry

Among blood donors in the US, 0.4% are homozygous for C282Y, indicating a carrier rate of around 12%

In Australia, the prevalence of C282Y homozygosity is 0.48% in men and 0.32% in women

Hemochromatosis is more common in men, with a male-to-female ratio of about 2:1 for clinical penetrance

In Ireland, the frequency of C282Y homozygotes is as high as 1 in 83

Non-HFE hemochromatosis accounts for less than 5% of cases in Europe but up to 20% in other populations

Juvenile hemochromatosis prevalence is rare, estimated at 1 in 1,000,000

In African Americans, HFE C282Y homozygosity is only 0.00014%

The HFE C282Y mutation originated about 60 generations ago in Celtic populations

Penetrance of C282Y homozygosity is 80% biochemical but only 25-30% clinical in men

In Canada, screening studies show 1 in 227 Caucasians are C282Y homozygotes

Neonatal screening detects hemochromatosis genotypes at 0.25-0.5% in US newborns of European descent

In Southern Europe, C282Y allele frequency drops to 5-10% compared to 10-15% in the north

African iron overload (Bantu siderosis) affects up to 10% of rural black South Africans

In porphyria cutanea tarda patients, 70-90% have HFE mutations contributing to iron overload

Type 2A hemochromatosis (HJV mutations) prevalence is 1-2 per million in Europe

Ferroportin disease (type 4) represents 2-10% of hemochromatosis cases in referral centers

In Asia, TMPRSS6 mutations linked to iron overload in 1-2% of cases mimicking hemochromatosis

US annual incidence of clinically diagnosed hemochromatosis is about 1 per 10,000

Women with C282Y homozygosity have 50% lower risk of clinical disease due to menstruation

In Utah population database, lifetime risk for C282Y homozygotes developing iron overload is 38% in men

Brazilian studies show C282Y homozygosity at 0.24% in general population

In French populations, H63D homozygosity prevalence is 1.5%

Neonatal hemochromatosis incidence is 1 in 100,000 live births

Alcoholics have 25-50% prevalence of HFE mutations

In Sardinia, HAMP mutations (type 2B) are found in 1:100,000

Global non-alcoholic fatty liver disease patients have 30% HFE mutation rate

In Iceland, C282Y frequency is 8.3% allele rate

Interpretation

Prevalence And Epidemiology Interpretation

Across populations of European ancestry, hereditary hemochromatosis type 1 is present in about 0.3 to 0.5 percent, with carrier frequencies near 1 in 10 for the HFE C282Y mutation and a higher clinical penetrance in men at roughly a 2 to 1 male to female ratio.

04 · Category

Symptoms And Diagnosis29 stats

Transferrin saturation >45% is first diagnostic marker, present in 90% of C282Y homozygotes before age 50

Serum ferritin >1000 ng/mL indicates significant iron overload in hemochromatosis

Liver biopsy shows grade 4 siderosis (4+ iron in hepatocytes) in 80% of untreated HH patients

MRI liver iron concentration >200 μmol/g predicts cirrhosis risk with 85% accuracy

Elevated transferrin saturation with normal ferritin occurs in 60% of presymptomatic C282Y homozygotes

Fatigue is reported in 75-90% of symptomatic hemochromatosis patients at diagnosis

Arthralgia, especially in metacarpophalangeal joints 2 and 3, affects 40-60% of patients

Hypogonadism due to pituitary iron deposition occurs in 30-50% of untreated men

Echocardiography shows diastolic dysfunction in 25% of asymptomatic HH patients

Genetic testing positive for C282Y homozygosity has 95% specificity for HH in high-risk populations

Fasting transferrin saturation >60% in men or >50% in women prompts HFE testing per AASLD guidelines

Serum ferritin rises at 20-30 μg/L per year in untreated C282Y homozygotes

Bronze diabetes (skin pigmentation + diabetes) classic triad in only 10-20% at presentation

Abnormal liver enzymes (ALT/AST >2x ULN) in 20-30% of presymptomatic HH

Superficial siderosis of skin biopsy confirms diagnosis in ambiguous cases

FibroScan liver stiffness >12 kPa indicates advanced fibrosis with 90% PPV in HH

Oral glucose tolerance test abnormal in 40% of HH patients without known diabetes

Polysomnography shows sleep apnea in 50% of symptomatic HH males

DEXA scan reveals osteoporosis in 25-40% of men with HH at diagnosis

Electrocardiogram QT prolongation in 15% due to iron cardiomyopathy

HLA typing historically used; A3-B14 haplotype in 80% of HH patients pre-HFE discovery

Serum iron >200 μg/dL with 90% saturation diagnostic in context of symptoms

Hepatic iron index (ferritin/age / liver iron conc) >1.9 confirms HH over secondary overload

Brain MRI shows basal ganglia hypointensity in 30% of advanced HH cases

Impotence reported by 45% of men at diagnosis, resolving with phlebotomy in 60%

Amenorrhea in 20-30% of premenopausal women with untreated HH

Audiometry reveals sensorineural hearing loss in 30% of HH patients

Fasting serum hepcidin <20 ng/mL in 95% of HH patients vs normals

Erythrocyte mean corpuscular volume low in 10% due to concurrent deficiencies

Interpretation

Symptoms And Diagnosis Interpretation

For symptom and diagnosis of hemochromatosis, a transferrin saturation above 45% appears in about 90% of C282Y homozygotes before age 50 and can be present with normal ferritin in 60% of presymptomatic cases, while classic presentation often includes fatigue in 75 to 90% and advanced liver iron findings such as grade 4 siderosis in 80% of untreated patients.

05 · Category

Treatment And Management26 stats

Phlebotomy response: ferritin decline 30-50 mg/L per 500 mL blood removed

Therapeutic phlebotomy targets ferritin <50 ng/mL, reducing mortality by 50%

Iron chelation with deferasirox 20-30 mg/kg/day normalizes ferritin in 70% of transfusion-dependent HH

Weekly phlebotomy of 500 mL removes 250 mg iron, sufficient for most adults

MRI monitoring post-phlebotomy shows LIC reduction of 40-60% in 12 months

Erythropoietin 10,000 U/week allows intensified phlebotomy in 80% without anemia

Liver transplant survival 5-year rate 80% in decompensated HH cirrhosis

Deferoxamine 40 mg/kg/night subcutaneous chelation mobilizes 30-50 mg iron/day

Family screening with genetic testing identifies 25% at-risk relatives needing intervention

Phlebotomy prevents diabetes progression in 60% of impaired glucose tolerant HH patients

Low-iron diet (<8 mg/day) augments phlebotomy efficacy by 20-30%

Vitamin C 500 mg/day enhances iron excretion during chelation by 2-3 fold

Tamoxifen reduces ferritin by 20% in HH with breast cancer comorbidity, anecdotal

Maintenance phlebotomy every 2-3 months keeps ferritin normal in 90% long-term

Deferiprone 75 mg/kg/day oral chelator effective in cardiac iron overload in HH

Early phlebotomy before ferritin >1000 prevents cirrhosis in 95% of cases

Hepatitis C co-infection requires antiviral therapy post-iron depletion, SVR 60%

Testosterone replacement normalizes hypogonadism in 70% after iron removal

Bisphosphonates improve BMD in HH osteoporosis post-phlebotomy, +5-10% at 2 years

CPAP for sleep apnea improves fatigue scores by 40% in HH patients

Ursodeoxycholic acid no benefit in HH cholestasis

Experimental hepcidin mimetics in trials reduce iron absorption by 70%

Phlebotomy reduces ALT by 50% within 6 months in 80% of patients

Insurance coverage for genetic testing improves screening compliance by 30%

Cirrhosis risk drops from 40% to <5% with phlebotomy before age 40

HCC surveillance with US/AFP every 6 months post-iron depletion, detects 70% early

Interpretation

Treatment And Management Interpretation

Under treatment and management, therapeutic phlebotomy and iron control can drive ferritin down 30 to 50 mg/L per 500 mL and target ferritin below 50 ng/mL, with reported mortality reduction of 50%, while chelation with deferasirox normalizes ferritin in 70% of transfusion dependent patients.

report visual · Breakdown

Key Outcomes in Hemochromatosis (Untreated vs Treated)

Untreated HH carries high organ complication rates, while early phlebotomy sharply lowers progression and cirrhosis risk.

60%

Liver failure mortality reduced from 60% to 10% with early phlebotomy

40%

Cirrhosis risk drops from 40% to <5% with phlebotomy before age 40

Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA

Rachel Svensson. (2026, February 13). Hemochromatosis Statistics. Gitnux. https://gitnux.org/hemochromatosis-statistics

MLA

Rachel Svensson. "Hemochromatosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hemochromatosis-statistics.

Chicago

Rachel Svensson. 2026. "Hemochromatosis Statistics." Gitnux. https://gitnux.org/hemochromatosis-statistics.

Key Takeaways

Related reading

Complications And Prognosis23 stats

Complications And Prognosis Interpretation

More related reading

Genetics And Molecular Biology25 stats

Genetics And Molecular Biology Interpretation

More related reading

Prevalence And Epidemiology30 stats

Prevalence And Epidemiology Interpretation

More related reading

Symptoms And Diagnosis29 stats

Symptoms And Diagnosis Interpretation

More related reading

Treatment And Management26 stats

Treatment And Management Interpretation

Key Outcomes in Hemochromatosis (Untreated vs Treated)

Cite This Report

Sources & references